INTERSECTION OF KIDNEY DISEASE AND CANCER: SHARED PATHWAYS AND CLINICAL CHALLENGES

Abstract

The convergence of kidney disease and cancer presents a growing clinical challenge, particularly as global populations age and the burden of chronic diseases escalates. This study explores the shared pathophysiological pathways, clinical outcomes, and therapeutic complications arising from the co-existence of chronic kidney disease (CKD) and malignancies. Through an integrated quantitative and qualitative methodology, we analyzed data from patients with dual diagnoses, focusing on disease prevalence, biomarker trends, treatment responses, and survival outcomes. The results highlight that renal cell carcinoma and bladder cancer are most prevalent among CKD patients, with significantly higher mortality observed in those with compromised renal function. Elevated nephrotoxicity was closely associated with agents such as cisplatin and methotrexate, while biomarkers like creatinine and NGAL demonstrated consistent trends of renal deterioration across various cancer treatments. Our figures captured critical patterns including the inverse relationship between glomerular filtration rate (GFR) and chemotherapy cycles, multi-dimensional survival-biomarker plots, and comparative quality-of-life scores. These findings underline the pressing need for integrated, interdisciplinary approaches in managing patients facing both renal and oncologic conditions. Furthermore, the visualizations and complex data tables enhance our understanding of predictive indicators and therapeutic implications. This research contributes a structured framework for clinicians and policymakers to anticipate risks, personalize treatment regimens, and improve long-term outcomes in this high-risk population.